Thalidomide administration inhibits the clinical evolution of the experimental autoimmune encephalomyelitis (eae) in lewis rats: preliminar results

ABSTRACT

Multiple sclerosis (MS) is a chronic neurodegenerative inflammatory disease of the central nervous system. Several immunomodulatory agents have been used to prevent MS acute exacerbations. Tumor Necrosis factor alpha (TNFα) and interferon gamma (IFN-γ) are two major inflammatory mediators. Recently, we investigated in our laboratory the therapeutic value of thalidomide, a recognized TNF-α inhibitor, for the treatment of MS using the classical Lewis rat model of experimental autoimmune encephalomyelitis ( EAE). The experimental study revealed that thalidomide reduces the incidence of EAE development in 90% of the cases. Hence we hypothesized that thalidomide may be an important therapeutical tool for prevention of acute exacerbations of the MS.